A 24 week, multi-centre, open label, non controlled study to assess the efficacy of valsartan in reducing albuminuria/proteinuria in hypertensive patients with type 2 diabetes mellitus.
Phase of Trial: Phase IV
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Valsartan (Primary)
- Indications Diabetic nephropathies; Hypertension; Proteinuria
- Focus Therapeutic Use
- Sponsors Novartis
- 07 May 2012 Actual patient number is 509 according to ClinicalTrials.gov.
- 07 May 2012 Status changed from active, no longer recruiting to completed.
- 07 May 2012 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.